Skip to content

Straberi Microneedling For Atrophic Acne

Clinical Trial Study for the Use of Straberi Microneedling Device to Treat Atrophic Acne Scarring

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04740268
Acronym
SAA
Enrollment
25
Registered
2021-02-05
Start date
2022-12-23
Completion date
2023-10-12
Last updated
2023-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrophic Acne Scar

Keywords

microneedling, atrophic acne, epistamp, universal skincare institute

Brief summary

This pilot study will expand knowledge and application needling using the Straberi microneedling device for the improvement of Atrophic Acne Scarring

Detailed description

This pilot study will expand the knowledge and application of needling using the Straberi microneedling device and its safety and benefits for improving the appearance of atrophic acne scarring. The pilot aims to objectively measure skin quality using the Derma Scan, photographs, and provide objective data showing improvement by way of the Goodman and Barons quantitative scar scale.

Interventions

DEVICEStraberi

The patient's entire face will be treated with the Straberi microneedling devise. The following settings will be used as a treatment protocol. Needle length between .02- 1.55 mm

Sponsors

Lavish Beauty
CollaboratorUNKNOWN
Universal Skincare Institute
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Participants in the Straberi microneedling trial are those who are seeking improvement for atrophic acne scaring.

Eligibility

Sex/Gender
ALL
Age
21 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Derma Scan showing aging including skin texture, wrinkles, brown spots, and pores. * Patients willing to sign informed consent. * Patients willing to be photographed and video documented * Patients willing to consent to 3 months of treatment

Exclusion criteria

* History of eczema in the treatment area; psoriasis and any other chronic skin conditions * History of actinic (solar) keratosis in the treatment area; * History of hemophilia * History of diabetes * The presence of raised moles, warts on the targeted area. * Collagen vascular diseases or cardiac abnormalities * Blood clotting problems * Active bacterial or fungal infection * Facial melanosis * Malignant tumors * Immunosuppression * Use of blood thinners or prednisone * Corticosteroids within two weeks of the procedure * Chronic liver disease * Porphyria or other skin diseases. * Patient not willing to sign informed consent. * TCA peels in the last 5 weeks * Subject currently has moderate to severe acne on the face. * Microneedling within the last 6 months * Subject has an active infection. * Subject has a history of a bleeding disorder * Subject has a history of keloidal tendency * Subject has received ablative or non-ablative laser treatments in the previous 6 months. * Subject has taken Accutane within the previous 3 months.

Design outcomes

Primary

MeasureTime frameDescription
Overall Patient satisfaction of skin improvement assessed by the Goodman and Barons quantitative scar scale.6 monthsA global quantitative grading system for assessing the disease load and global severity of disease in a patient with post acne scarring. The Goodman and Baron score considers type of scar, number of scars, and severity of scarring and assigns a grade 1-4 with grade 1 representing mild, macular disease and grade 4 representing severe scarring that is obviously visible at social distances of 50cm, is not easily covered by makeup, and is not able to be flattened by manual stretching of the skin. Lower scores are favorable. Scale will be completed at every office visit over the 6 month study.
The Global Aesthetic Improvement Scale (GAIS)6 monthsThe Global Aesthetic Improvement Scale (GAIS) is a 5-point scale rating global aesthetic improvement in appearance, compared to pretreatment, as judged by the investigator 5 point scale ranging from 1 to 5 with 5 = The appearance has worsen compared with the original condition and 1 = Excellent corrective results

Secondary

MeasureTime frameDescription
Overall Skin changes assessed by Derma Scan6 monthsThe Derma Scan System utilizes two special lighting systems (RGB +UV) and smart skin analyzer software that allows two images (before and after care) to be compared side by side, which can be used to detect the changes in skin
Overall Skin changes assessed by Acne Scar Subtypes6 monthsSkin improvement assessed by Acne Scar Subtypes for improvement of acne scarring rolling, icepick, and or boxcar subtypes.Ice pick scars are narrow, sharply demarcated, V-shaped tracts, \<2 mm in diameter, that extend into the deep dermis or even subcutaneous layer. Boxcar scars are wider (1-4 mm in diameter), U-shaped tracts, with sharp, vertical edges that extend 0.1-0.5 mm into the dermis. Rolling scars are characterised by dermal tethering of the dermis to the subcutis. They are generally ≥4 mm in diameter, irregular, with a rolling or undulating appearance.Scale will be completed at every office visit over the 6 month study.
Photographs6 monthsDigital imaging device using a grid background with controlled lighting and setting to grade acne scar improvement on a quartile grading scale(1 = 1% to 25%, 2 = 26 to 50%, 3 = 51 to 75%, 4 = \>76% improvement).
To evaluate the impact on the quality of life (DLQI)6 monthsThe Dermatology Life Quality Index questionnaire (DLQI) is 10 questions were asked to the patients and score is 0-3 for each question. The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026